Postgraduation Program of Tropical Medicine Foundation of Amazonas / University of the State of Amazonas, Manaus, Brazil, Department of Surgery, School of Medicine, Federal University of Amazonas, Manaus, Brazil.
Cancer Cytopathol. 2011 Jun 25;119(3):167-76. doi: 10.1002/cncy.20143. Epub 2011 Mar 1.
Protein p16(INK4a) immunocytochemistry (ICCp16) has the potential to reveal lesions at risk of progression to anal cancer. This study examined measures of diagnostic validity of ICCp16 in HIV-positive patients treated at the Tropical Medicine Foundation of Amazonas in the coloproctology outpatient clinic.
One hundred ninety HIV-positive patients were consecutively enrolled in 2007 and 2008. All patients underwent anal cytologic sampling to perform ICCp16 in conventional and GluCyte (Synermed International, Westfield, Indiana and S¸ao Paulo, Brazil) smears and also for genotyping of human papillomavirus (HPV). Patients were then subjected to anal biopsies monitored by high-resolution anoscopy. Hematoxylin-eosin and immunoperoxidase p16 (clone 6H12) stains were performed in slides with biopsied and cytological specimens, respectively. HPV genotyping on anal scrapings was performed by a polymerase-chain reaction (PCR)-based method. The immunochemical findings were compared with histopathological and PCR results in contingency tables and analyzed by nonparametric tests. Measures of diagnostic validity of ICCp16 were calculated. Statistical significance was set at P ≤ .5.
There was no statistically significant association between the immunochemical results (conventional or GluCyte smears) and histopathological or HPV genotyping findings (P > .05). In the best scenario, ICCp16 presented 31% sensitivity and 81% specificity for the diagnosis of anal squamous intraepithelial lesion (ASIL) and 30% and 66%, respectively, for the diagnosis of infection with high-risk HPV.
There was no association between ICCp16 results and histopathological findings nor between ICCp16 and HPV genotyping. ICCp16 showed poor sensitivity and moderate specificity for the diagnosis of ASIL or high-risk HPV.
蛋白 p16(INK4a)免疫细胞化学(ICCp16)有可能揭示有进展为肛门癌风险的病变。本研究在亚马孙热带医学基金会的结直肠门诊检查了 ICCp16 在 HIV 阳性患者中的诊断有效性。
2007 年和 2008 年连续纳入了 190 名 HIV 阳性患者。所有患者均接受了肛门细胞学采样,以便在常规和 GluCyte(印第安纳州西菲尔德的 Synermed International 和巴西圣保罗的 GluCyte)涂片上进行 ICCp16,并对人乳头瘤病毒(HPV)进行基因分型。然后,对接受高分辨率肛门镜监测的患者进行肛门活检。对活检和细胞学标本分别进行苏木精-伊红和免疫组化 p16(克隆 6H12)染色。在肛门刮取物上通过聚合酶链反应(PCR)方法进行 HPV 基因分型。在 contingency tables 中比较免疫化学发现与组织病理学和 PCR 结果,并通过非参数检验进行分析。计算 ICCp16 的诊断有效性指标。统计学意义设定为 P ≤.5。
免疫化学结果(常规或 GluCyte 涂片)与组织病理学或 HPV 基因分型结果之间没有统计学显著关联(P >.05)。在最佳情况下,ICCp16 对肛门鳞状上皮内病变(ASIL)的诊断敏感性为 31%,特异性为 81%,对高危 HPV 感染的诊断敏感性为 30%,特异性为 66%。
ICCp16 结果与组织病理学发现之间没有关联,也与 HPV 基因分型之间没有关联。ICCp16 对 ASIL 或高危 HPV 的诊断敏感性差,特异性适中。